Nuvalent Target of Unusually High Options Trading (NASDAQ:NUVL)

Nuvalent, Inc. (NASDAQ:NUVL) was the recipient of some unusual options trading activity on Tuesday. Stock traders bought 5,384 call options on the stock. This represents an increase of approximately 9,870% compared to the average daily volume of 54 call options.

Wall Street Analysts Forecast Growth

Several analysts have commented on NUVL shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nuvalent in a research note on Tuesday, April 21st. Wells Fargo & Company assumed coverage on Nuvalent in a report on Monday, March 30th. They issued an “overweight” rating and a $116.00 target price on the stock. Sanford C. Bernstein started coverage on Nuvalent in a report on Thursday, May 21st. They set an “outperform” rating and a $189.00 price target for the company. Piper Sandler lowered shares of Nuvalent from an “overweight” rating to a “neutral” rating in a research report on Tuesday. Finally, Leerink Partners set a $165.00 price objective on shares of Nuvalent in a research report on Wednesday, June 3rd. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Nuvalent has a consensus rating of “Moderate Buy” and an average price target of $138.50.

Nuvalent Price Performance

Shares of NASDAQ NUVL traded up $34.34 during trading on Tuesday, hitting $122.83. 33,404,190 shares of the company were exchanged, compared to its average volume of 885,991. Nuvalent has a 1 year low of $71.13 and a 1 year high of $122.94. The company has a market cap of $9.70 billion, a price-to-earnings ratio of -20.27 and a beta of 1.15. The firm’s fifty day moving average price is $102.38 and its 200 day moving average price is $102.97.

Nuvalent (NASDAQ:NUVL) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($1.39) EPS for the quarter, missing the consensus estimate of ($1.35) by ($0.04). During the same quarter in the previous year, the business posted ($1.18) EPS. On average, research analysts forecast that Nuvalent will post -5.74 earnings per share for the current year.

Nuvalent News Summary

Here are the key news stories impacting Nuvalent this week:

• Positive Sentiment: Nuvalent agreed to be acquired by GSK for roughly $10.6 billion in cash, valuing the cancer drug developer at a substantial premium and sending the stock sharply higher. Reuters: UK’s GSK to buy US-based cancer drugmaker Nuvalent for $10.6 billion
• Positive Sentiment: The deal gives GSK ownership of three lung cancer drug candidates, including two that are already under FDA review, highlighting the value of Nuvalent’s pipeline and supporting the takeover price. WSJ: GSK to Buy Nuvalent for $10.6 Billion in Oncology Push
• Neutral Sentiment: Market commentary also notes the deal is part of GSK’s broader effort to strengthen its oncology franchise and offset future patent pressure in other businesses, which explains the strategic rationale behind the acquisition. Proactive Investors: GSK agrees $10.6bn Nuvalent takeover to bolster oncology pipeline

Insider Buying and Selling at Nuvalent

In other Nuvalent news, insider Henry E. Pelish sold 3,093 shares of Nuvalent stock in a transaction on Thursday, April 9th. The shares were sold at an average price of $104.48, for a total value of $323,156.64. Following the transaction, the insider directly owned 65,604 shares in the company, valued at approximately $6,854,305.92. The trade was a 4.50% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO James Richard Porter sold 30,000 shares of the stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $101.69, for a total transaction of $3,050,700.00. Following the sale, the chief executive officer owned 324,879 shares of the company’s stock, valued at $33,036,945.51. This trade represents a 8.45% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 96,953 shares of company stock worth $9,956,364 in the last 90 days. Company insiders own 5.02% of the company’s stock.

Institutional Investors Weigh In On Nuvalent

Institutional investors have recently modified their holdings of the company. Bank of America Corp DE grew its holdings in shares of Nuvalent by 20.0% in the 1st quarter. Bank of America Corp DE now owns 216,516 shares of the company’s stock worth $22,182,000 after acquiring an additional 36,147 shares during the period. Tri Locum Partners LP grew its holdings in Nuvalent by 0.4% in the first quarter. Tri Locum Partners LP now owns 308,506 shares of the company’s stock valued at $31,606,000 after purchasing an additional 1,135 shares during the last quarter. EverSource Wealth Advisors LLC grew its holdings in Nuvalent by 141.3% in the first quarter. EverSource Wealth Advisors LLC now owns 333 shares of the company’s stock valued at $34,000 after purchasing an additional 195 shares during the last quarter. California State Teachers Retirement System increased its position in shares of Nuvalent by 29.7% in the first quarter. California State Teachers Retirement System now owns 49,670 shares of the company’s stock valued at $5,089,000 after buying an additional 11,386 shares in the last quarter. Finally, Royal Bank of Canada increased its position in shares of Nuvalent by 1,537.9% in the first quarter. Royal Bank of Canada now owns 23,569 shares of the company’s stock valued at $2,414,000 after buying an additional 22,130 shares in the last quarter. Hedge funds and other institutional investors own 97.26% of the company’s stock.

Nuvalent Company Profile

Nuvalent, Inc (NASDAQ:NUVL) is a clinical-stage precision oncology company focused on the discovery, development and commercialization of targeted therapies for patients with genetically defined cancers. Founded in 2019 and headquartered in San Diego, California, Nuvalent applies structure-guided drug design to develop small molecule inhibitors that address key oncogenic drivers. The company’s research platform integrates insights from cancer biology, medicinal chemistry and translational science to create therapies with differentiated selectivity and potency against validated targets.

Nuvalent’s lead pipeline candidates include NVL-520, a highly selective RET inhibitor designed to minimize off-target effects, and NVL-655, a potent covalent inhibitor targeting KRAS G12D mutations.